Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 118   

Articles published

JNJ 107.78 +0.74 (0.69%)
price chart
Johnson & Johnson May Settle 1000 More DePuy ASR Hip Claims for $250 M
On the heels of Johnson & Johnson's win this week in its Pinnacle Hip implant trial, the pharmaceutical giant may offer $250 million to settle lawsuits not included in its previous offer to settle thousands of DePuy ASR hip claims from last year ...
Johnson & Johnson Considering Paying $250 Million To Settle More Hip ...  Bidness ETC
More DePuy ASR Hip Implant Cases Near Settlement  Legal Examiner
Related articles »  
Johnson & Johnson Plans Ebola Vaccine Testing
Johnson & Johnson will begin safety testing in early January on a vaccine combination that could protect people from a strain of the deadly Ebola virus.
Johnson & Johnson accelerates Ebola vaccine testing amid heightened anxiety  The Star-Ledger
Ebola: Johnson & Johnson to start vaccine trials in January
Related articles »  
John J. Heldrich, former top executive at Johnson & Johnson and civic leader ...
Widely considered one of New Jersey's top business and civic leaders, Heldrich spent 41 years at Johnson & Johnson before retiring in 1991.
Johnson & Johnson to Begin Testing Ebola Vaccine in January
Johnson & Johnson said it would begin testing an Ebola-virus vaccine in humans in January and could have 250,000 doses available in May, if health authorities deem it safe and promising enough to distribute more broadly.
Testing for Ebola Vaccines to Start Soon, WHO Says  New York Times
Related articles »  
Johnson & Johnson heiress pens book
A decade ago, Johnson & Johnson heir Jamie Johnson won acclaim for profiling pampered pals including Ivanka Trump and Georgina Bloomberg in his HBO doc, ´┐ŻBorn Rich.
Johnson & Johnson's DePuy wins first trial over Pinnacle hips
NEW YORK/DALLAS (Reuters) - Johnson & Johnson was found not liable by a Texas jury on Thursday in the first case to go to trial over whether Pinnacle hip implants made by the company's DePuy Orthopedics unit were defective.
Why Johnson & Johnson (JNJ) Stock Is Higher Today
Johnson & Johnson Wins First Pinnacle Hip Implant Trial  Businessweek
Related articles »  
One Put, One Call Option To Know About for Johnson & Johnson
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson Johnson & Johnson (NYSE: JNJ). So this week we highlight one interesting put contract, and one interesting call ...
Related articles »  
Is Johnson & Johnson's Worst Nightmare Becoming Reality?
Johnson & Johnson (NYSE: JNJ ) has been one of the few top healthcare companies to post strong growth within its pharmaceutical segment this year.
Related articles »  
J&J sales top forecast, helped by drug for hep C
At the end of September, Johnson & Johnson announced plans to buy Alios BioPharma, a biotech company focused on developing existing therapies for viral diseases.
Why I'm in Johnson & Johnson for the long run  The Globe and Mail
Johnson & Johnson Quarterly Profit Rises on Sale of Unit  Businessweek
Related articles »  
Market Reaction To Johnson & Johnson's Earnings Is Justified
Johnson & Johnson's stock price fell sightly following its Q3 2014 earnings announcement despite the company beating consensus estimates and keeping the full year outlook the same.